[CARA] Cara Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 135.31 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 9.97 Change: 0.77 (8.37%)
Ext. hours: 10.13 Change: 0.16 (1.6%)

chart CARA

Refresh chart

Strongest Trends Summary For CARA

CARA is in the medium-term down -28% in 6 months. In the long-term up 108% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate includes intravenous CR845, which has completed Phase II clinical trials for the treatment acute postoperative pain in adult patients. The company is also developing Oral CR845 that has completed Phase I clinical trial for the treatment of moderate-to-severe acute and chronic pain; and CR701, which is in preclinical trial for treating neuropathic and inflammatory pain. Cara Therapeutics, Inc. was founded in 2004 and is based in Shelton, Connecticut.

Fundamental Ratios
Shares Outstanding27.28 M EPS-2.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -49.06% Sales Growth - Q/Q-46.5% P/E-6.79
P/E To EPS Growth P/S38.79 P/BV2.85 Price/Cash Per Share
Price/Free Cash Flow ROA-36.88% ROE-40.17% ROI
Current Ratio14.31 Quick Ratio Long Term Debt/Equity Debt Ratio0.07
Gross Margin Operating Margin-555.3% Net Profit Margin-546.19% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities-10 K Cash From Operating Activities-5.24 M Gross Profit
Net Profit-4.69 M Operating Profit-4.72 M Total Assets51.65 M Total Current Assets49.06 M
Total Current Liabilities3.43 M Total Debt800 K Total Liabilities4.23 M Total Revenue490 K
Technical Data
High 52 week23.95 Low 52 week11.6 Last close15.25 Last change0.33%
RSI67.7 Average true range0.88 Beta1.58 Volume1.26 M
Simple moving average 20 days6.82% Simple moving average 50 days-7.24% Simple moving average 200 days-11.66%
Performance Data
Performance Week-2.68% Performance Month8.54% Performance Quart-21.39% Performance Half-29.4%
Performance Year23.78% Performance Year-to-date17.31% Volatility daily3.73% Volatility weekly8.33%
Volatility monthly17.07% Volatility yearly59.14% Relative Volume252.99% Average Volume603.3 K
New High New Low

News

2019-03-13 21:50:08 | Edited Transcript of CARA earnings conference call or presentation 12-Mar-19 8:30pm GMT

2019-03-13 13:01:47 | Here's Why Cara Therapeutics Stock Rose as Much as 13.9% Today

2019-03-13 12:15:00 | These Four Marijuana Stocks Are Raising Eyebrows on Wednesday

2019-03-13 00:19:42 | Cara Therapeutics Inc CARA Q4 2018 Earnings Conference Call Transcript

2019-03-12 17:35:01 | Stocks making the biggest moves after hours: Switch, Clearwater Paper and more

2019-03-12 17:20:09 | Cara Therapeutics CARA Reports Q4 Loss, Tops Revenue Estimates

2019-03-12 16:27:34 | Cara: 4Q Earnings Snapshot

2019-03-12 16:01:00 | Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-12 10:00:00 | Top Cannabis Plays-THC Therapeutics, Inc

2019-03-07 08:57:01 | Athersys ATHX Q4 Earnings: What's in Store for the Stock?

2019-03-07 08:51:01 | Is a Beat in Store for Catabasis CATB This Earnings Season?

2019-03-05 16:01:00 | Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

2019-03-04 06:41:11 | Can Segmental Growth Aid Cooper Companies' COO Q1 Earnings?

2019-03-03 10:15:00 | Better Buy: Cara Therapeutics vs. Scotts Miracle-Gro Company

2019-02-22 16:43:09 | What's in Store for Vericel VCEL This Earnings Season?

2019-02-15 08:20:00 | Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 — Fundamental Analysis, Key Performance Indications

2019-02-13 13:47:53 | Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks?

2019-02-12 09:00:00 | Biotech Plays in the News You Should Know

2019-02-11 13:56:07 | Here's Why Cara Therapeutics Stock Rose 17.3% in January

2019-02-08 12:10:00 | These 4 Marijuana Stocks Are Looking Strong

2019-02-06 14:45:00 | Watch These Marijuana Stocks Hit The Ground Running On Wednesday 2/6/19

2019-02-05 08:00:00 | Biotech Stocks to Watch

2019-02-02 13:11:11 | New Cannabis Products Which Could Disrupt the Industry in 2019

2019-01-31 16:09:56 | Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

2019-01-31 08:30:00 | Biotechs Investors Are Flocking To

2019-01-30 15:00:02 | Analyzing CARA, INSY, and GWPH’s Earnings Trends

2019-01-30 13:30:02 | Cannabis Stocks: CARA, INSY, and GWPH’s Revenue Trajectory

2019-01-30 11:58:56 | CARA, INSY, and GWPH: Analysts’ Recommendations in January

2019-01-29 08:30:00 | Cannabis and Biotech Stocks that Could Explode

2019-01-28 08:00:00 | Biotech Stocks to Watch this Week

2019-01-24 12:08:40 | Is Cara Therapeutics a Buy?

2019-01-24 08:10:00 | Consolidated Research: 2019 Summary Expectations for First Data, IDEXX Laboratories, CMS Energy, Worthington Industries, Triumph Group, and Cara Therapeutics — Fundamental Analysis, Key Performance Indications

2019-01-23 13:30:02 | Cara Therapeutics: Earnings Trends and Recent Developments

2019-01-23 12:00:02 | Cara Therapeutics: A Financial Overview in January

2019-01-23 10:26:26 | Cara Therapeutics Has Risen ~18% in January

2019-01-21 10:53:42 | Top Marijuana Stocks on the NASDAQ

2019-01-18 09:36:42 | With Trial Results Due, This Could Be a Breakout Year for Cara Stock

2019-01-16 11:01:27 | These Cannabis Stocks Are Soaring in January

2019-01-15 11:10:53 | Bank Of America Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results

2019-01-11 16:55:02 | How Is INSYS Therapeutics Financially Positioned in January?

2019-01-10 21:19:00 | Here's Why Cara Therapeutics Fell 28.5% in December

2019-01-10 16:20:01 | A Look into GW Pharmaceuticals’ Revenue Trends

2019-01-07 07:00:00 | Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ CR845/ difelikefalin Injection in Hemodialysis Patients with Pruritus

2019-01-04 17:11:31 | Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine?

2019-01-03 17:43:10 | Cara CARA Up on IDMC's Recommendation to Continue Trial

2019-01-02 07:00:00 | Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

2018-12-23 03:38:30 | Is Casa Therapeutics Inc CARA Going to Burn These Hedge Funds?

2018-12-21 10:30:02 | What’s Auxly Cannabis’ MidStream Strategy in 2018?

2018-12-19 12:20:00 | Cara Therapeutics Stock Could Outperform in 2019

2018-12-18 08:45:00 | 4 Marijuana Stocks To Watch On Tuesday 12/18/2018